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Objectives The goal of these studies was to determine the association between cardiovascular autonomic neuropathy (CAN)
and indices of left ventricle (LV) structure and function in patients with type 1 diabetes (T1DM) in the DCCT/EDIC
(Diabetes Control and Complications Trial /Epidemiology of Diabetes Interventions and Complications) study.
Background The pathophysiology of LV dysfunction in T1DM remains unclear, especially when the LV ejection fraction (EF) is
preserved. Whether CAN is associated with LV dysfunction is unclear.
Methods Indices of LV structure and function were obtained by cardiac magnetic resonance imaging (CMRI). CAN was
assessed by cardiovascular reflex testing (R-R response to paced breathing, Valsalva ratio, and blood pressure
response to standing). Analyses were performed in 966 DCCT/EDIC participants with valid CMRI and CAN data
(mean age 51 years, 52% men, mean diabetes duration 29 years, and mean glycosylated hemoglobin 7.9%).
Results Systolic function (EF, end-systolic and end-diastolic volumes, stroke volumes) was not different in 371 subjects
with CAN compared with 595 subjects without CAN. In multiple-adjusted analyses, participants with either ab-
normal R-R variation or a composite of abnormal R-R variation, abnormal Valsalva ratio, and postural blood
pressure changes had significantly higher LV mass, mass-to-volume-ratio, and cardiac output compared with
those with normal tests (p  0.0001 for all). After further adjustment for traditional cardiovascular risk factors,
subjects with abnormal R-R variation had higher LV mass and cardiac output compared with those with a nor-
mal R-R variation (p  0.05).
Conclusions In this large cohort of patients with T1DM, CAN is associated with increased LV mass and concentric remodeling
as assessed by CMRI independent of age, sex, and other factors. (Diabetes Control and Complications Trial [DCCT];
NCT00360815) (Epidemiology of Diabetes Interventions and Complications [EDIC]; NCT00360893) (J Am
Coll Cardiol 2013;61:447–54) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.10.028Cardiovascular disease (CVD) is a major cause of mortality
among patients with type 1 diabetes (T1DM). In T1DM,
left ventricular (LV) dysfunction may precede or occur in
the absence of coronary artery disease or hypertension, often
seen in the setting of a normal ejection fraction (EF) (1–4),
and its pathophysiology remains unclear. Diastolic dysfunc-
tion, characterized by impairment in LV relaxation and
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diabetic cardiomyopathy (2,5). Our group has found that
diastolic dysfunction detected early in the course of T1DM
is correlated with abnormal cardiac sympathetic function as
assessed by cardiac sympathetic imaging (4). Cardiovascular
autonomic neuropathy (CAN) complicates T1DM and is
an independent predictor of mortality in affected patients
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Autonomic Neuropathy and LV Dysfunction in Diabetes January 29, 2013:447–54(6–8). Despite the frequent co-
occurrence of these cardiac com-
plications (4), whether there is a
relationship between CAN and
LV dysfunction in T1DM has not
been clearly determined.
The development and progres-
sion of CVD and CAN in patients
with T1DM has been a focus of
the DCCT (Diabetes Control and
Complications Trial)/EDIC (Epi-
demiology of Diabetes Interven-
tions and Complications) study
since its inception (9), and many
factors associated with the risk of
cardiovascular events in T1DM
have been examined in EDIC
prospectively (9).
In addition, DCCT/EDIC
was the first large study to use
cardiac magnetic resonance im-
aging (CMRI) to assess myocar-
dial structure and function in pa-
tients with T1DM, the reference
standard for assessment of LV
structure and function (10). The
most recent CAN evaluations
were obtained during DCCT/
EDIC years 13 to 14 and 16 to
17, and CMRI evaluations were
obtained during DCCT/EDIC
years 14 to 16. These evaluations
provided us with a unique oppor-
tunity to explore the relationship
between CAN and LV structure
and function in this well-
characterized cohort of patients
and to gain new insights into the
mechanisms underlying myocar-
dial dysfunction in T1DM.
Methods
Subjects. DCCT and EDIC have been described else-
here (11–13). Briefly, 1,441 subjects with T1DM for 1 to
5 years with no (primary prevention cohort) or minimal
secondary intervention cohort) diabetic retinopathy were
nrolled in DCCT. Subjects were randomly assigned to
ither intensive or conventional treatment and were fol-
owed for 3 to 9 years (mean 6.5 years) (12). At the end of
CCT, intensive therapy was recommended for all sub-
ects, subjects in the conventional treatment group were
rained in intensive therapy, and all subjects returned to
heir own healthcare providers for diabetes care. Annual
DIC examinations began in 1994, 1 year after completion
Abbreviations
and Acronyms
ACEi  angiotensin-
converting enzyme inhibitor
AER  albumin excretion
rate
ARB  angiotensin
receptor blocker
BP  blood pressure
CAN  cardiac autonomic
neuropathy
CMRI  cardiac magnetic
resonance imaging
CVD  cardiovascular
disease
DBP  diastolic blood
pressure
EF  ejection fraction
HbA1c  glycosylated
hemoglobin
HDL  high-density
lipoprotein
LDL  low-density
lipoprotein
LV  left
ventricle/ventricular
LVEDV  left ventricular
end-diastolic volume
LVESV  left ventricular
end-systolic volume
LVSV  left ventricular
stroke volume
MRI  magnetic resonance
imaging
SBP  systolic blood
pressure
SSFP  steady-state free
precession
T1DM  type 1 diabetesf the DCCT, and 1,375 (96%) of former DCCT subjectsconsented to participate in EDIC. A detailed description of
EDIC study procedures and baseline characteristics has
been published (11). During EDIC, clinical and biochem-
ical endpoints were obtained annually by history, physical
examination, and laboratory testing (13). Glycosylated he-
moglobin (HbA1c) and blood pressure (BP) were measured
nnually, and lipid profiles and urinary albumin excretion
ates (AER) were obtained on alternate years. DCCT/
DIC procedures were approved by institutional review
oards of all participating centers. Written informed con-
ent was provided by all participants.
CMRI with contrast (gadolinium) was performed during
DIC years 14 to 16, and CAN evaluations were performed
uring EDIC years 13 to 14 and again during years 16 to 17.
mong the surviving EDIC cohort at year 14, 1,259 with no
adolinium contraindications were eligible for CMRI, and
,122 (89%) consented to the procedure (Fig. 1). Ninety-four
ubjects were excluded because of contraindications to the
xamination (e.g., claustrophobia, metal in the orbit), and
1 subjects had CMRI examinations of insufficient quality
or analysis, yielding a completion rate of 81% (1,017 of
,259).
CAN testing was performed in 1,226 subjects during
ears 13 to 14 and in 1,185 subjects during years 16 to 17 of
DIC. Subjects who experienced hypoglycemia after mid-
ight (blood glucose 50 mg/dl or signs/symptoms of
ypoglycemia [n 4]) and subjects with acute illnesses 48 h
efore testing (n  1) were excluded from CAN testing.
ubjects with proliferative retinopathy, recent history of laser
herapy or vitrectomy, and/or no eye examination in the last 4
ears (n  34) and those who could not perform the required
orced expiration (n  25) were excluded from the Valsalva
aneuver (Fig. 1).
MRI Protocol. Among 25 scanning centers, 11 centers
sed Siemens 1.5-T magnetic resonance imaging (MRI)
canners (Siemens, Munich, Germany), 10 used General
DCCT Cohort
N = 1,441
C AN T E ST
N = 1,185 
C M R I
N = 1,017 
C AN T E ST  and C M R I
N = 966 
EDIC Cohort
N = 1,375
Eligible CAN 1,204 Eligible MRI 1,122
Figure 1 Flow Diagram of DCCT/EDIC Participation
in CAN and CMRI Evaluations
CAN  cardiovascular autonomic neuropathy; CMRI  cardiac magnetic reso-
nance imaging; DCCT  Diabetes Control and Complications Trial; EDIC 
Epidemiology of Diabetes Interventions and Complications; MRI  magnetic
resonance imaging.
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United Kingdom), and 4 used Philips MRI scanners
(Philips Medical Systems, Best, the Netherlands). CMRI
examinations included short- and long-axis cine images for
LV function, myocardial tagging for regional function, and
delayed gadolinium images for myocardial scar. The proto-
col used localizing images, followed by horizontal and
vertical long-axis cine images obtained using an
electrocardiogram-gated steady-state free precession (SSFP)
pulse sequence with temporal resolution 50 ms, spatial
resolution 1.4  1.8  8 mm, and 2-mm gap between
hort-axis slices. Short-axis cine SSFP images were ob-
ained beginning 1 cm above the mitral valve plane and
xtending to the apex of the LV. The temporal resolution
or all SSFP cine images was 50 ms with 30 reconstructed
ine phases. All images were obtained during breath holding
t resting lung volume.
CMRI studies were read at the Johns Hopkins Hospital
y readers masked to all clinical and laboratory data.
hort-axis cine images were analyzed using QMASS soft-
are (version 6.0, Medis, the Netherlands). LV contours
ere checked by a senior cardiac trained MR physician with
5 years’ experience. The endocardial and epicardial borders
f the LV were outlined at end-diastole and end-systole on
hort-axis cine images. The papillary muscles were included
n the left ventricular end-diastolic volume (LVEDV) and
eft ventricular end-systolic volume (LVESV), and excluded
rom the LV mass. Re-reads of LV mass and volumes were
erformed for 100 randomly selected studies to calculate
ntraclass correlations. The quality of each series of the
MRI exams was subjectively scored by the reading center
s 0 to 2, with 0 indicating nondiagnostic, 1 acceptable, and
good quality. An overall examination quality score was
iven by averaging the scores of the individual series. The
ean quality score was 1.8  0.2.
LVEDV and LVESV were calculated using Simpson’s
ule (summation of areas on each separate slice multiplied by
he sum of slice thickness and image gap). LV mass was
etermined by the sum of the myocardial areas (the differ-
nce between endo- and epicardial contours) multiplied by
lice thickness plus image gap in the end-diastolic phase
ultiplied by the specific gravity of myocardium (1.05
/ml). Left ventricular stroke volume (LVSV) was calcu-
ated as the difference between LVEDV and LVESV. LV
F was calculated as LVSV divided by LVEDV multiplied
y 100 (percent). The mass-to-volume ratio was calculated
s LVDM divided by LVEDV. Cardiac output was calcu-
ated as LVSV multiplied by the heart rate.
ssessment of CAN. Standardized CAN evaluations
R-R response to paced breathing [R-R variation], Valsalva
aneuver, and postural changes in BP) were performed as
escribed (14,15) (Fig. 2). Before CAN testing, all subjects
ere asked to fast, avoid caffeine and tobacco products for
h before the test, and hold all prescription and over-the-ounter medicines (except for basal insulin) until testing wasompleted (14,15). CAN testing was performed with Ho-
anson ANS2000 devices (Hokanson, Bellevue, Washing-
on), and results were analyzed at a single reading center. All
AN measurements were reviewed by a single masked
nvestigator (P.A.L.), who determined whether the techni-
al quality of the recording and conditions of the test met
tudy criteria. Intrasubject reproducibility of the CAN tests
as evaluated using same-day, test–retest on a random
ubset of 185 subjects across EDIC sites, and revealed high
est–retest correlations for R-R variation and Valsalva
kappa  0.7766 and 0.8034, respectively, p  0.0001 for
oth).
CAN was defined as either an R-R variation 15
abnormal R-R) or a composite CAN index that included
-R variation 20 plus Valsalva ratio 1.5 or a decrease of
10 mm Hg in diastolic blood pressure (DBP) upon
tanding (CAN) (DCCT original definition) (14,16).
tatistical analyses. Data entry, management, and analyses
ere performed at the DCCT/EDIC Data Coordinating
enter using SAS version 9.2 statistical analysis software
Cary, North Carolina).
Demographic and clinical characteristics were compared
sing the Wilcoxon rank sum test to evaluate group differ-
nces (normal vs. abnormal CAN) for ordinal and numeric
ariables. The contingency chi-square test was used for
ategorical variables.
Separate multivariate linear regression models were used
o calculate the least square means of LV function after
djusting for age, sex, DCCT cohort assignment (primary/
econdary), and machine type. Means and standard errors
ere compared for subjects with normal versus abnormal
-R variation or CAN. Additional models adjusted for
eight, weight, smoking, alcohol use, systolic blood
ressure (SBP), high-density lipoprotein (HDL) choles-
erol, low-density lipoprotein (LDL) cholesterol, and
bA1c. Cardiac output models were further adjusted for
resting heart rate.
Regression estimates and standard errors present the
change in LV function per unit change in the independent
variable of interest. The proportion of variability explained
in the reduced model with only the CVD risk factors as
Verify test 
preparedness
30 MIN SUPINE 
REST
R-R
PACED 
BREATHING
6 MIN
∆BP
STAND
10 MIN
SUPINE 
REST
15 MIN
VR 1
SUPINE 
REST
5 MIN
VR 2
Figure 2 Flow Diagram of CAN Testing
BP  blood pressure; VR  Valsalva ratio.predictors was compared with the proportion of variability
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Autonomic Neuropathy and LV Dysfunction in Diabetes January 29, 2013:447–54in the full model with all CVD risk factors, height, weight,
and either abnormal R-R or composite CAN.
SBP, HDL cholesterol, LDL cholesterol, and HbA1c
were included in the analyses as time-weighted mean values
calculated over the entire DCCT/EDIC study period up
until the year 16 to 17 CAN evaluation.
Characteristics of Participants With ConcomitantAN Measurements and CMRI Measureme ts (N  966)Table 1 Characteristics of Participan With ConcomitantCAN Measurements and CMRI Measurements (N  966)
Characteristic
Normal CAN
Measures
(n  595)
Abnormal CAN
Measures
(n  371)
Female 277 (47) 183 (49)
Primary prevention cohort 322 (54) 154 (42)*
Age, yrs 49.3 6.6 52.5 6.6*
Age at diagnosis, yrs 20.3 7.9 22.1 7.9*
Body mass index, kg/m2 28.1 4.7 28.5 5.0
Diabetes duration, yrs 28.7 4.9 30.1 4.8*
HbA1c, % 7.7 1.1 8.1 1.3*
Height, cm 171.9 9.5 172.0 9.8
Weight, kg 83.4 16.5 84.5 17.4
Current cigarette smoker 45 (8) 57 (15)*
Current alcohol use 284 (48) 159 (43)
Log(AER) 2.5 1.1 3.0 1.5*
GFR CKD-EPI definition, ml/min/1.73 m2 96.6 14.2 87.2 23.8*
Heart rate 66 10 72 12*
Treated hypertension† 327 (55) 284 (78)*
Treated hypercholesterolemia‡ 366 (62) 276 (75)*
Beta-blocker use 29 (5) 66 (18)*
Any ACEi or ARB use 301 (51) 250 (68)*
DCCT/EDIC time-weighted variables
HbA1c, % 7.7 0.8 8.3 1.0*
HDL cholesterol, mg/dl 56 13 55 13
LDL cholesterol, mg/dl 106 20 112 20*
Triglycerides, mg/dl 78 36 90 44*
Systolic blood pressure, mm Hg 117 8 121 8*
Diastolic blood pressure, mm Hg 74 5 75 6*
Values are n (%) or mean  SD. *p  0.01 †Hypertension is defined as systolic blood pressure
140 mm Hg, diastolic blood pressure 90 mm Hg, documented hypertension, or the use of
antihypertensive agents for the treatment of hypertension. ‡Hypercholesterolemia is defined as
LDL cholesterol 130 mg/dl or the use of lipid-lowering agents.
ACEi  angiotensin-converting enzyme inhibitor; AER  albumin excretion rate; ARB  angio-
tensin receptor blocker; CAN cardiac autonomic neuropathy; CKD-EPI Chronic Kidney Disease
Epidemiology Collaboration; CMRI cardiac magnetic resonance imaging; DCCT/EDIC Diabetes
Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications; GFR
glomerular filtration rate; HbA1c glycosylated hemoglobin; HDL high-density lipoprotein; LDL
low-density lipoprotein.
Minimally Adjusted Association Between Indices of LV Function anTable 2 Minimally Adjusted Association Between Indices of LV
Cardiac Function
Normal R-R
(n  649)
Abnormal R-R
(n  315)
End-diastolic volume, ml 135.6 1.1 136.3 1.5
End-systolic volume, ml 52.5 0.6 52.6 0.9
Stroke volume, ml 83.1 0.7 83.7 1.0
Ejection fraction, % 61.6 0.3 61.9 0.4
Cardiac output, l/min 5.7 0.1 6.2 0.1
LV mass, gm 134.6 1.0 142.4 1.5
Mass-to-volume ratio, gm/ml 1.00 0.01 1.06 0.01
Values are least square mean SE, adjusted for concurrent age, sex, cohort assignment (primary/
of 10 mm Hg in DBP upon standing as defined in Methods.
DBP  diastolic blood pressure; LV  left ventricular; other abbreviations as in Table 1.Results
A description of CMRI measurements in EDIC partici-
pants and their relationship to CVD risk factors has been
published (17). This analysis included 966 T1DM subjects
with concomitant CMRI and CAN measurements. The
demographic and clinical characteristics of this middle-age
cohort (mean age 51  7 years, 52% males) are shown in
able 1. Hypertension (defined as SBP 140 mm Hg/or
BP 90 mm Hg or use of antihypertensive agents) was
resent in 64% of subjects, smoking was reported by 11%,
ean LDL cholesterol was 108  20 mg/dl. Nonpartici-
ants, including those who died, did not differ from partic-
pants in most characteristics (Online Table 1).
There were 371 subjects with CAN and 315 subjects with
bnormal R-R variation only. As shown in Table 1, CAN
nd abnormal R-R subjects were more likely to be older, in the
econdary prevention cohort, have longer diabetes duration,
nd have higher HbA1c, albumin excretion rate (AER), SBP,
LDL cholesterol levels, and resting heart rate.
The association between indices of CAN (CAN and
abnormal R-R variation) and CMRI indices are shown in
Table 2. In a model adjusted for age, sex, cohort assignment
(primary/secondary), and machine type, cardiac parameters
of systolic function (EF, LVESV, LVEDV, and stroke
volume) were not different in subjects with CAN compared
with subjects without CAN. However, CAN subjects or
those with abnormal R-R variation had higher LV mass and
mass-to-volume-ratios compared with subjects without
CAN (p  0.0001 for all), changes consistent with LV
concentric remodeling (Table 2). Subjects with abnormal
R-R variation and CAN subjects also had significantly
higher cardiac output (p  0.0001). To evaluate whether
CAN is an independent risk factor for the changes in LV
mass and geometry, the model included the weighted mean
HbA1c during DCCT/EDIC, and other covariates (height,
eight, current smoking, current alcohol use, mean SBP,
ean HDL, and mean LDL) previously shown (17) to be
ssociated with CMRI-derived measures of LV structure in
he EDIC participants. In this multivariate analysis, subjects
ith abnormal R-R variation had significantly higher LV
ass and cardiac output compared with those with normal
Variation or CAN at EDIC Year 16/17tion and R-R Variation or CAN at EDIC Year 16/17
p Value
CAN
(n  595)
CAN
(n  371) p Value
0.6895 135.7 1.1 135.9 1.4 0.9121
0.9095 52.7 0.6 52.3 0.8 0.6848
0.6057 83.0 0.7 83.6 0.9 0.5920
0.4477 61.5 0.3 62.0 0.3 0.2324
0.0001 5.7 0.1 6.1 0.1 0.0001
0.0001 134.4 1.1 141.4 1.4 0.0001
0.0001 1.00 0.01 1.05 0.01 0.0001
ary), and machine type. CAN included R-R variation20 plus Valsalva ratio1.5 or a decreased R-RFunc
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higher in subjects with an abnormal R-R variation and
CAN after adjusting for resting heart rate (p  0.003 and
p  0.01, respectively; data not shown). The associations
between CAN and LV mass and mass-to-volume ratio
were no longer significant. The effects of CAN on LV
function were not different in men versus women.
To better understand these findings, we performed multi-
variable analysis to evaluate the proportion of variability ex-
plained by CVD risk factors and to define how the addition of
CAN measures into the model affects the change in risk for the
CMRI indices of LV structure and function. Table 4 shows
the proportion of variability associated with 9 CVD factors on
those CMRI indices that were different in participants with
CAN compared with participants without CAN, and the effect
of the R-R variation on the absolute change in R2. The full
odel also adjusted for height and weight.
Adding R-R variation improved the performance of the
odel for all indices of LV structure and function. R2
increased by 11.4% for cardiac output, and 8.5% for LV
Association Between Indices of LV function and R-R Variation or Cfter Adjustm nt for Traditional Cardia Risk Factors nd GlycemiaTable 3 Associatio Between In ices of LV function nd R-R VAfter Adjustment for Traditional Cardiac Risk Factors a
Cardiac Function
Normal R-R
(n  649)
Abnormal R-R
(n  315)
End-diastolic volume, ml 135.9 1.4 137.7 1.6
End-systolic volume, ml 52.9 0.9 53.2 1.0
Stroke volume, ml 82.9 0.9 84.4 1.0
Ejection fraction, % 61.5 0.4 61.9 0.4
Cardiac output, l/min 5.8 0.1 6.2 0.1
LV mass, gm 140.3 1.3 143.6 1.5
Mass-to-volume ratio, gm/ml 1.04 0.01 1.06 0.01
Values are least square mean  SE, adjusted for concurrent age, sex, cohort assignment (primary
ean LDL, and mean HbA1c. CAN included RR variation 20 plus Valsalva ratio 1.5 or a dec
Abbreviations as in Tables 1 and 2.
Multivariable Analysis of R-R Variation and CVD Risk Factors in ReTable 4 Multivariable Analysis of R-R Variation and CVD Risk F
Cardiac Function Cardiac
CVD risk factor
Age, yrs 0
Sex, female vs. male 0
Cohort, prim vs. scnd 0
Smoking, yes vs. no 0
Alcohol use, yes vs. no 0
Mean SBP, mm Hg 0
Mean HDL, mg/dl 0.0
Mean LDL, mg/dl 0.0
Mean HbA1c, % 0
Proportion of variability (R2) explained by CVD risk factors‡
CAN risk factor
Abnormal R-R, yes vs. no 0
Proportion of variability (R2) explained by CVD risk factors
and abnormal R-R§
Increase in R2
Values are estimates (standard error) from full model. *p  0.01; †p  0.05. ‡Reduced model inc
and is adjusted for all CVD risk factors in the first column, as well as height, weight, and machine typ
(CVD risk factors  abnormal R-R).
CVD  cardiovascular; prim  primary;. scnd  secondary; SBP  systolic blood pressure; other abbremass. Similar results were observed with the composite
CAN (not shown). Before adding R-R variation into the
model, mean SBP, mean HbA1c, and smoking accounted
or most of the 20% variability in the LV mass-to-volume
atio. Abnormal R-R variation was associated with an
3.3-g higher LV mass compared with normal R-R, which
as higher than the LV mass change observed with the
ncrease per mean unit SBP. To account for the possible
mpact of drugs used as part of the standard of care in T1DM
n CVD risk factors, we added beta-blocker and angiotensin-
onverting enzyme inhibitor (ACEi)/angiotensin receptor
lockers (ARBs) use to these models and found no significant
ffects (Online Table 2). Similarly, we found no significant
nteractions between diabetes duration and age on the relation-
hip between CAN/R-R variability and CMRI findings.
iscussion
his study examined the association between CAN and
ndices of LV structure and function as assessed by CMRI
EDIC Year 16 to 17on or CAN at EDIC Year 16 to 17
lycemia
p Value
CAN
(n  595)
CAN
(n  371) p Value
0.2866 136.3 1.4 136.8 1.5 0.7277
0.7922 53.3 0.9 52.7 1.0 0.5856
0.1662 83.0 0.9 84.1 1.0 0.2858
0.3656 61.4 0.4 62.0 0.4 0.1652
0.0001 5.8 0.1 6.1 0.1 0.0003
0.0352 140.7 1.3 142.6 1.4 0.2155
0.2490 1.04 0.01 1.05 0.01 0.3499
dary), machine type, height, weight, current smoking, current alcohol use, mean SBP, mean HDL,
f 10 mm Hg in DBP upon standing as defined in Methods.
to LV Functionrs in Relation to LV Function
t (l/min) LV Mass (g) Mass-to-Volume Ratio (g/ml)
.01)* 0.42 (0.11)* 0.0002 (0.001)
.12) 22.53 (2.12)* 0.08 (0.02)*
.08)† 4.24 (1.38)* 0.01 (0.01)
.12) 8.17 (2.23)* 0.07 (0.02)*
.08)† 1.60 (1.39) 0.02 (0.01)
.01)* 0.99 (0.10)* 0.01 (0.001)*
.003) 0.02 (0.06) 0.001 (0.0004)
.002) 0.06 (0.04) 0.0003 (0.0003)
.04) 0.36 (0.80) 0.02 (0.01)*
53.1% 20.7%
.09)* 3.34 (1.58)† 0.01 (0.01)
61.6% 21.8%
8.5% 1.1%
ll CVD risk factors in the first column as well as machine type. §Full model includes R-R variation
olute difference in proportion of variability from reducedmodel (only CVD risk factors) to full modelAN atriati
nd G
/seconlationacto
Outpu
.03 (0
.17 (0
.19 (0
.13 (0
.15 (0
.03 (0
04 (0
03 (0
.03 (0
21.8%
.34 (0
33.2%
11.4%
ludes a
e. Absviations as in Tables 1 and 2.
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Autonomic Neuropathy and LV Dysfunction in Diabetes January 29, 2013:447–54in patients with T1DM. No significant differences in EF
and other indices of LV function were observed between
participants with and without CAN. However, the presence
of CAN was associated with higher LV mass and structural
changes, suggesting concentric remodeling. Measures of
CAN were also associated with higher cardiac output.
Several studies (1,2,4,5,18) have reported that myocardial
dysfunction may occur in the absence of coronary artery
disease among patients with T1DM. Alterations of diastolic
(2,4,5) and systolic (19) function are reported in otherwise
healthy diabetic subjects, and often predate the development
of macrovascular complications. This could suggest either
direct metabolic effects on the heart, the contribution of
microvascular disease (20), or the effects of other factors,
including CAN. In prior smaller studies, we and others have
found associations between CAN and diastolic dysfunction
in patients with T1DM (2,4,5,21). Sacre et al. (3) reported
that in patients with T2DM, measures of both systolic and
diastolic function were associated with measures of CAN.
In a more recent study, Dinh et al. (22) found that among
subjects with T2DM or impaired glucose tolerance referred
for elective coronary angiography, subjects with CAN had a
higher prevalence and a more severe form of LV diastolic
dysfunction, independent of the presence of coronary artery
disease or other covariates.
Diastolic dysfunction, characterized by impairment in LV
relaxation and passive filling, is considered to be the earliest
manifestation of diabetic cardiomyopathy (2,5). Although
direct indices of diastolic function were not available for this
analysis, our data demonstrate that abnormalities in R-R
variation, arguably the most sensitive index of cardiovascular
autonomic dysfunction, and the composite index of CAN
were strongly associated with an increased LV mass and
evidence of concentric hypertrophy in subjects with normal
EF. The pattern of LV concentric remodeling (23,24) was
shown to carry an increased risk for CVD events (25),
independent of LV hypertrophy (24).
Increased LV wall thickness and LV hypertrophy are
described as causes of diastolic dysfunction and are, in
general, due to myocardial structural changes, including
altered or increased extracellular matrix collagen content
and post-translational modification of structural cardiomy-
ocyte proteins (26).
Excessive sympathetic activation, which is described in
the early stages of CAN in diabetes due to an initial
predominant parasympathetic denervation (7,27), may also
promote LV hypertrophy through its impact on sympa-
thovagal balance and baroreflexes. The cardiovascular reflex
tests used to assess CAN in this study are essentially
measures of cardiovagal function, and some have argued
that impaired heart rate variability as measured by time-
and-frequency domain indices may be more sensitive. How-
ever, studies that assessed the diagnostic accuracy against
the reference standard of cardiovascular reflex tests found
only fair agreement (28).The vagal component of the
baroreflex is a major protective mechanism that adjusts heartrate, stroke volume, and BP to minimize myocardial stress.
A depressed baroreflex is associated with an unopposed
sympathetic tone, increased SBP (29), LV wall stress, and
subsequent LV hypertrophy and increased risk of heart
failure and CVD (30–32). Although baroreflex sensitivity
was not directly measured in this study, several studies have
reported early impairment of baroreflex sensitivity in pa-
tients with diabetes (33,34). Sympathetic activation associ-
ated with earlier stages of CAN may also promote myocar-
dial injury and LV remodeling via abnormal myocardial
norepinephrine signaling, catecholamine toxicity (35), oxi-
dative stress–induced myocardial cytotoxic effects (36),
calcium-dependent apoptosis, and myocardial fibrosis
(36 –38).
Increased LV mass is associated with incomplete ventric-
ular relaxation, a clinical variable of diastolic dysfunction, in
patients with normal EF (39). With incomplete relaxation,
the myocardium remains in an activated state that can be
described as a partial diastolic contracture. Traditionally,
incomplete relaxation was believed to be associated with
either high-rate tachycardia or increased LV stiffness
(39,40). CAN  T1DM subjects had significantly higher
heart rates than subjects without CAN. This may also
contribute to incomplete relaxation in patients with LV
hypertrophy compared with patients with normal LV
mass (39).
A stiff, noncompliant ventricle has been shown to be a
determinant of the diastolic properties of the LV, including
incomplete relaxation (41,42). Although the majority of
patients with diastolic dysfunction and normal EF are
asymptomatic at rest, symptoms may develop with exertion,
stress, or tachycardia. Such patients are at risk for the
development of acute-onset heart failure symptoms. Exer-
cise intolerance is one of the first symptoms in patients with
diastolic dysfunction and in patients with CAN. An in-
crease in LV diastolic pressures and pulmonary venous
pressures is 1 of the proposed mechanisms associated with
exercise intolerance in patients with LV diastolic dysfunc-
tion with normal EF. These observations suggest possible
differences in the components of diastolic dysfunction be-
tween rest and dynamic conditions, which may have clinical
relevance.
LV hypertrophy, defined by increased LV mass, has been
shown to be a powerful, independent predictor of CVD
mortality (43). Similarly, CAN has been shown to strongly
predict CVD mortality in patients with diabetes (6,44,45),
independent of traditional CVD risk factors (6). Therefore,
the association of LV hypertrophy and CAN may contrib-
ute to increased mortality risk in these patients and may
require more aggressive management of modifiable risk
factors.
Acceptance of isolated diastolic dysfunction as the earliest
(and primary) cardiac abnormality in patients with diabetes
(18) might also reflect the insensitivity of commonly used
indices for identifying earlier stages of abnormal LV systolic
function. The ongoing evaluations with CMRI tagging
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magnitude of changes on subclinical measures such as LV
torsion and strain in this cohort of patients with T1DM.
A strong association was found between measures of
CAN and higher cardiac output. Cardiac output is con-
trolled by chronotropic and inotropic cardiac adaptive
mechanisms, and is modulated by autonomic tone and
innervation of the heart (46,47). Thus, the higher resting
heart rate observed in subjects with CAN contributed to the
higher observed cardiac output in these subjects. Differences
in stroke volume associated with cardiac denervation and
with changes in ventricular filling time (48) and baroreflex
sensitivity (47,48) may have also played a role. Increased
cardiac output has been associated with high-output cardiac
failure (49) through mechanisms that involve changes in
systemic vascular resistance and neurohormonal activation
(49). Recent studies have also linked a high cardiac output
to LV hypertrophy (50). In our study, the presence of CAN
was associated with both LV hypertrophy and higher
cardiac output.
Study strengths include the large number of standardized,
high-quality CMRI and CAN evaluations performed. Ad-
ditionally, this cohort of patients with T1DM has been
followed for more than 20 years and carefully characterized
for many other cardiovascular risk factors and microvascular
and macrovascular complications.
Study limitations. The study is limited by its cross-
sectional nature, preventing analysis of any causal relation-
ship between CAN and LV dysfunction. It is further limited
by the lack of concomitant CMRI and CAN evaluations in
20% of the EDIC participants.
Conclusions
In summary, in this cohort of patients with T1DM, the
presence of CAN was associated with increased LV mass
and with concentric remodeling as assessed by CMRI,
independent of age, sex, and other traditional CVD risk
factors. Because both LV hypertrophy and CAN have been
associated with diastolic dysfunction and increased CVD
mortality, patients with this combined phenotype may be at
increased risk for CVD and may benefit from early and
more aggressive risk factor management. Studies targeting
aggressive risk factor management in this patient population
are warranted.
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For supplemental tables and a list of the participating radiologists and
technologists in the DCCT/EDIC Research Group, please see the Online
Appendix. A complete list of the individuals and institutions participating in
the DCCT/EDIC Research Group can be found in Archives of Ophthalmol-
ogy, 2008:126(12):1713.
